Compare HCA Health Inc (HCA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Lam Research Corporation — how do they compare? HCA Health Inc trades at $413.88 (market cap $89.08B), while Lam Research Corporation trades at $327.98 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 4.4× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.76%). Which is the better fit depends on your goals.
| HCA | LRCX | |
|---|---|---|
Market Cap | $89.08B | $389.67B |
Sector | Health | Technology |
52-Week High | $545.13 | $433.33 |
52-Week Low | $361.32 | $97.03 |
Enterprise Value | $139.62B | $387.83B |
Dividend Yield | 0.76% | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.
HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.
Lam Research (LRCX) trades at $328.93, up 7.35% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $18.44B, net income of $5.36B (31.27% margin), and consistent earnings beats. Recent expansion into panel-level packaging and semiconductor workforce development initiatives position LRCX for continued AI-driven growth.
Outlook remains positive with 78% analyst buy ratings and $397.18 consensus price target, though elevated valuation ratios (P/E 54.06) and potential semiconductor cycle volatility present risks. The stock offers exposure to AI infrastructure growth but requires monitoring of competitive threats and capital expenditure trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
